/ACE.ST
ACE.ST Stock - Ascelia Pharma AB (publ)
Healthcare|BiotechnologySTO
$3.17-1.09%
$0.04 (-1.09%) • Dec 23
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACE.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.14 – $3.20
TARGET (TP)$3.65
STOP LOSS$2.92
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.06
52W High$5.23
52W Low$2.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-938,000 | $-1,049,000 | $-3,892,000 | $-8,723,000 | $-825,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-68,124,000 | $-110,914,000 | $-147,007,000 | $-137,948,000 | $-93,428,000 |
| Net Income | $-80,029,000 | $-109,288,000 | $-131,223,000 | $-125,903,000 | $-98,697,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.48 | $-3.24 | $-3.77 | $-3.82 | $-3.76 |
Company Overview
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ACE.STBeat Rate
33%
Last 12 quarters
Avg Surprise
-21.3%
EPS vs Estimate
Beats / Misses
4/8
Last 12 quarters
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+38.0%
$-0.31vs$-0.50
Q2 24
-25.0%
$-0.50vs$-0.40
Q3 24
-39.3%
$-0.39vs$-0.28
Q4 24
-110.0%
$-0.42vs$-0.20
Q1 25
-45.0%
$-0.29vs$-0.20
Q2 25
-15.0%
$-0.23vs$-0.20
Q3 25
-140.7%
$-0.20vs$0.50
Q4 25
-33.4%
$-0.13vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | $-0.10 | $-0.13 | -33.4% | ✗ MISS |
Q3 2025 | Aug 21, 2025 | $0.50 | $-0.20 | -140.7% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.20 | $-0.23 | -15.0% | ✗ MISS |
Q1 2025 | Feb 7, 2025 | $-0.20 | $-0.29 | -45.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.20 | $-0.42 | -110.0% | ✗ MISS |
Q3 2024 | Aug 15, 2024 | $-0.28 | $-0.39 | -39.3% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.40 | $-0.50 | -25.0% | ✗ MISS |
Q1 2024 | Feb 9, 2024 | $-0.50 | $-0.31 | +38.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.90 | $-0.63 | +30.0% | ✓ BEAT |
Q3 2023 | Aug 18, 2023 | $-0.90 | $-1.19 | -32.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | — | $-1.07 | — | — |
Q1 2023 | Feb 10, 2023 | $-2.44 | $-1.59 | +35.1% | ✓ BEAT |
Q4 2022 | Nov 4, 2022 | — | $-0.77 | — | — |
Q3 2022 | Aug 18, 2022 | — | $-0.68 | — | — |
Q2 2022 | May 11, 2022 | — | $-0.58 | — | — |
Q1 2022 | Feb 10, 2022 | $-4.74 | $-0.86 | +81.8% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | — | $-0.82 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-1.01 | — | — |
Q2 2021 | May 12, 2021 | — | $-1.00 | — | — |
Q1 2021 | Feb 16, 2021 | — | $-1.25 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ACE.ST
What is ACE.ST's current stock price?
Ascelia Pharma AB (publ) (ACE.ST) is currently trading at $3.17 per share. The stock has moved -1.09% today.
What is the analyst price target for ACE.ST?
No analyst price targets are currently available for this stock.
What sector is Ascelia Pharma AB (publ) in?
Ascelia Pharma AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is ACE.ST's market cap?
Ascelia Pharma AB (publ) has a market capitalization of $0.37 billion, making it a small-cap company.
Does ACE.ST pay dividends?
No, Ascelia Pharma AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorELIC.ST
Elicera Therapeutics AB (publ)
$5.59
Mkt Cap: $0.3B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
IRLAB-A.ST
IRLAB Therapeutics AB (publ)
$1.97
Mkt Cap: $0.2B
ISOFOL.ST
Isofol Medical AB (publ)
$0.72
Mkt Cap: $0.2B
IVACC.ST
Intervacc AB (publ)
$0.92
Mkt Cap: $0.3B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
LIPUM.ST
Lipum AB (publ)
$14.55
Mkt Cap: $0.3B
MAGLE.ST
Magle Chemoswed Holding AB (publ)
$17.20
Mkt Cap: $0.4B
MOB.ST
Moberg Pharma AB (publ)
$10.04
Mkt Cap: $0.5B
XINT.ST
Xintela AB (publ)
$0.27
Mkt Cap: $0.2B
Explore stocks similar to ACE.ST for comparison